Metastatic prostate cancer (PCa) is initially treated with androgen ablation therapy, which causes regression of androgen-dependent tumors. However, these tumors eventually relapse resulting in recurrent castrationresistant prostate cancer (CRPC). Currently, there is no effective therapy for CRPC and the molecular mechanisms that lead to the development of CRPC are not well understood. Here, we evaluated the hypothesis that combined inhibition of Hedgehog (Hh) Finally, non-competitive inhibition of AR, but not competitive inhibition, was effective at limiting the activity of truncated AR leading to the inhibition of CRPC.
Introduction
Prostate cancer (PCa) is the second most common cause of death from cancer in men of all ages and is the leading cancer diagnosed, approximately 1 in 6 American men will be diagnosed with prostate cancer during his lifetime (1). Estimated new cases and deaths from prostate cancer in the United States for 2012 include 241,740 new cases and 28,710 deaths (National Cancer Institute Facts and Figure, 2012 , www.cancer.gov/cancertopic/types/prostate). Initial treatment for PCa involves androgen ablation therapy which causes regression of androgen-dependent tumors, however patients eventually fail this therapy and die of recurrent castration-resistant prostate cancer (CRPC) (2). Yet, the molecular mechanisms that promote the development of CRPC are not fully understood. Currently there is no effective therapy for CRPC and the median survival after the development of CRPC is 20-24 months (3;4). It is known that prostate tumors can select for genetic and epigenetic changes that confer growth advantage like any other cancer cells (5). Similar processes are believed to be responsible for the development of CRPC (6;7). For example, prostate tumors that recur after androgen ablation therapy have been shown to have amplified AR gene, resulting in increased AR expression (8;9) and hypersensitivity to low levels of circulating androgens. Certain growth factors such as epidermal growth factor (EGF) have been shown to activate AR in the absence of androgen (10). Overexpression of anti-apoptotic protein Bcl-2 is seen in CRPC (11). All of the above mechanisms lead to the development of CRPC under androgen depleted condition. AR protein is organized into an N-terminal domain that comprises of the transactivation function, DNA binding domain (DBD) and a hinge region connected to the C-terminal domain or ligand binding domain (LBD) (12) . AR is a member of a larger family of nuclear receptors that is activated by the binding of androgenic hormones testosterone or dihydrotestosterone (13;14) . AR upon ligand binding in the cytosol translocates to the nucleus and acts as a DNA binding transcription factor where it interacts with other factors upon binding to DNA and controls the transcription of androgen-regulated genes, thereby stimulating development and maintenance of male sexual phenotype (13;15-17) . Prostate cancer is androgen dependent (18) . Because AR activity is dependent on ligand binding, its activity can be blocked by competitive inhibitors such as bicalutamide. On the other hand, Dehm and Tindall demonstrated the expression of truncated AR (lacking LBD) in CRPC cells that were insensitive to bicalutamide treatment (19) . Hence, a non-competitive inhibitor of AR is required to inhibit truncated AR activity in CRPC cells.
Here we report the use of pyrvinium pamoate, which was shown to be a non-competitive inhibition of AR activity (20) , to inhibit AR activity in CRPC cells.
Recent studies have demonstrated that hedgehog (Hh) signaling and other developmentally important signaling pathways are upregulated in cancer stem-like cells leading to their proliferation, invasion, metastasis and development of resistance to drug-induced apoptosis (21;22) . Two studies showed that Hh signaling activity is increased in CRPC cells as compared to androgen dependent prostate cancer (ADPC) cells (23;24) suggesting that Hh signaling might contribute to the development and maintenance of CRPC. Mammalian Hh ligands are secreted lipid-modified proteins including sonic (Shh), Indian (Ihh), and Desert (Dhh) hedgehog. Shh is most ubiquitously expressed in mammals (25) Given the important roles played by truncated AR and Hh signaling pathway in CRPC, in the current study, we further characterized their expression and function in various in vitro and in vivo models and tested our hypothesis that the combination of inhibition of both Hh and AR pathway may generate a synergistic blockade of CRPC progression. Our results show that a combined inhibition of Hh and AR signaling pathways using Smo inhibitors and a non-competitive AR inhibitor may be a novel effective therapeutic strategy to inhibit CRPC development and progression.
Materials and Methods: Chemicals
Smo inhibitor LDE225 was provided by Novartis through a material transfer agreement, Other Smo inhibitors Cyclopamine (LC Laboratories, MA) and GDC0449 (LC Laboratories, MA) were purchased.
The non-competitive inhibitor of AR (pyrvinium pamoate) and the competitive inhibitor of AR (biclutamide [Casodex]) were purchased from Sigma, MO.
Cell Cultures
LNCaP and 22Rv-1 cells were originally from the American Type Culture Collection (ATCC, VA). The culture was maintained in McCoy's 5A medium supplemented with pyruvate, L-serine, L-arginine, Lglutamine, 100X nonessential amino acids for MEM, MEM amino acids without L-glutamine, MEM vitamins, penicillin, streptomycin, gentamycin, sodium bicarbonate and 10% fetal bovine serum (FBS).
Androgen independent LNCaP and 22Rv-1 cells, which were called LNCaP AI and 22Rv-1 AI, were cultured in the above mentioned McCoy's 5A medium with 10% charcoal-stripped FBS instead of regular 10% FBS. Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 was obtained from ATCC and maintained in RPMI-1640 medium supplemented with 10% FBS, penicillin and streptomycin. 
Animal experiments
Four to five-week-old male athymic nude mice (Harlan Sprague-Dawley, Inc. IN) were used for this study.
Animals were maintained under the care and supervision of the Laboratory Animal Research facility at the University of Texas Health Science Center, San Antonio, Texas. The animal protocol was approved and monitored by the Institutional Animal Care and Use Committee.
Orthotopic and Subcutaneous injections
Briefly, 22Rv-1 AI/Luc-GFP cells were harvested from subconfluent, exponentially growing cultures. The cells were inoculated into the dorso-lateral prostate or dorsal lower back of anesthetized male nude mice for orthotopic or subcutaneous injections respectively, with a 27-gauge needle attached to a 1-ml syringe. Each 
Bioluminescence imaging analysis
Bioluminescence imaging analysis was used to monitor orthotopic tumor growth in mice for ranking and grouping the mice according to their tumor burden for different drug treatments. Mice were anesthetized and D-luciferin (Xenogen, Alameda, CA) was injected i.p at 75 mg/kg in PBS. Xenogen IVIS-Spectrum
Imaging system was used to acquire bioluminescence images at 10 min after injection. Acquisition time was set at 60 seconds at the beginning and reduced later on in accordance with signal strength to avoid saturation. Analysis was performed using LivingImage software (Xenogen) by measurement of photon flux (measured in photons/s/cm 2 /steradian) with a region of interest (ROI) drawn around the bioluminescence signal to be measured. Orthotopic tumor burden was based on photon flux in the ROI around the major bioluminescence signal in the prostate.
Cell proliferation assay
Cells were plated in a 96-well plate at 1,000 cells/well in triplicates. After treatment with LDE225, GDC0449, Cyclopamine, Casodex, and PP individually or in combination for 5 days, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, MO) solution (2mg/ml) was added and incubated for 2 hours in a tissue incubator. The blue colored formazon product was dissolved in DMSO and quantified at 595 nm wavelength on a Biotek plate reader.
Western Blot Analysis
Cells were harvested and lysed in Laemmli buffer with a cocktail of protease inhibitors. The total protein concentrations were quantified by the BCA protein assay (Thermo Scientific, Rockford, IL). An equal amount of total protein was resolved by SDS-PAGE, transferred to a nitrocellulose membrane under constant voltage and blocked with 5% non-fat dried milk in TBST (10mM Tris pH 7.5, 150mM NaCl and 0.05% Tween-20) followed by washing with TBST. Primary antibodies and secondary antibodies were diluted in TBST and applied with a washing step in between. Proteins were detected using the Amersham ECL Western blotting detection kit (GE Healthcare, Piscataway, NJ, USA). Antibody to AR was from Santa Cruz, CA, to Actin from Sigma, MO and to GAPDH from CalBioChem, MA.
Soft Agar Colony Formation Assay
Cells in 1 ml of 0.4% low melting agarose (Invitrogen, NY) with culture medium were plated at 3,000 cells/well on top of existing 0.8% agarose in 6-well plates. The wells were covered with 1 ml of culture medium containing various treatments and incubated at 37 °C in a 5% CO2 incubator for the indicated number of days. Visualized colonies with diameter >30µm were counted after staining with piodonitrotetrazolium violet (Sigma, MO) overnight.
Real-time PCR
Real-time PCR was performed using Brilliant SYBR Green QPCR Master Mix (Stratagene, La Jolla, CA) 
Small interfering RNA (siRNA)
LNCaP AD cells were transfected with AR siRNA using Lipofectamine 2000 (Invitrogen, NY). AR was silenced using siRNA pool SMARTpool, siAR #1 purchased from Dharmacon (Catalogue number M003400-00, Waltham, MA).
In vitro luciferase assay
Cells were seeded in triplicates in a 12-well plate at a density of 1.8×10 5 cells/well. When cultures were about 80% confluent, they were co-transfected with 0.2 μg of β-galactosidase expression plasmid and 1µg
of PSA or Gli responsive promoter-luciferase construct using Lipofectamine 2000 (Invitrogen, NY) in a serum-free medium following the manufacturer's protocol. After 5 h, the medium was replaced with the serum containing medium. After overnight incubation, the cells were lysed in a buffer (100 mM K 2 HPO4, 1 mM DTT, and 1% Triton X-100) and the luciferase activity in the cell lysate was measured as previously described (28) . Luciferase activity was normalized for transfection efficiency with β-galactosidase activity.
Statistical analysis
All statistical analyses were performed using the two-tailed Student's t-tests or One-way analysis of variance followed by Tukey-Kramer post-hoc test. Only values with a P-value < 0.05 was considered as statistically significant. Error bars represent mean ± SEM. we generated CWR22 human prostate cancer xenograft tumors subcutaneously in athymic male nude mice that were implanted with slow-releasing testosterone pellet for 90 days. After the tumors reached an approximate 800 mm 3 , the mice were castrated and the testosterone pellet removed to provide an androgen independent condition for the xenograft tumors. Mice 2 and 5 were euthanized and tumors isolated after their tumors reached 800 mm 3 in the AD condition, whereas mice 12 and 14 were castrated and testosterone pellet removed after their tumors reached 800 mm 3 and these mice were maintained in the AI condition for 14 days before euthanization and isolation of their tumors. RNA isolated from mice 2, 5, 12 and 14 showed a relative increase in AR expression in tumors from mice 12 and 14 (AI condition) compared to tumors from mice 2 and 5 (AD condition) (Fig. 1C) . Also there was a relative increase in the level of AR expression in mouse prostate gland after castration compared to mouse prostate gland before castration (Fig. 1D) . We also found that the expression of AR was relatively increased in PCa tissues from patients treated with hormone deprivation therapy as compared to PCa tissues from patients without hormone deprivation therapy through an analysis of gene microarray data in Oncomine database from a published study (29) (Fig. 1E ).
Results

Androgen deprivation increases
We next investigated whether relatively increased AR expression in AI condition compared to AD condition correlates with its activity. Surprisingly, we found a relative decrease in AR activity under AI condition in comparison to AD condition (Fig 2) . We assessed for the AR activity by a PSA promoter luciferase reporter assay, in which an AR-responsive promoter sequence of PSA gene with a firefly luciferase (PSA-Luc) reporter plasmid was co-transfected with a β-gal expression plasmid into LNCaP and 22Rv-1 (AD and AI) cells. The relative Luc unit (RLU) is the Luc activity normalized by β-gal activity in the same cell lysate. There was a relative decrease in PSA expression in AI cells as compared to AD cells ( Fig. 2A) . Also the relative PSA expression was lower in AI cells in comparison to AD cells as assessed by quantitative real time PCR (Fig. 2B) . To confirm these results in an in vivo model, we used the previously described CWR22 xenograft mouse model and found that upon castration the PSA mRNA level was relatively lower in comparison to non-castrated or androgen dependent tumors (Fig. 2C) . Furthermore, immunocytochemical staining showed a more uniform nuclear localization of AR in AD cells than in AI cells (Fig. 2D) . Consistently, immunohistochemical staining also showed that castration led to an increased cytoplasmic localization of AR castrated mouse prostate tissue when compared to the prostate gland tissue of non-castrated mice (Fig. 2E) . These data clearly demonstrate that although AR expression is increased under AI condition, the activity of AR is relatively lowered in the AI condition in both in vitro and in vivo studies due to its reduced nuclear localization. Our results demonstrating a decrease in AR activity with increase in AR levels are consistent with a recently published report (30) , in which active AR was shown to negatively regulate AR expression.
Increased Truncated AR (AR ΔLBD) expression in AI cells. Earlier reports have demonstrated the presence of COOH-terminally truncated AR protein isoform lacking the AR ligand binding domain (LBD)
and denoted as AR ΔLBD in 22Rv-1 prostate cancer cells (31 with non-competitive AR antagonist, pyrvinium pamoate (PP), which does not interact with AR LBD (20) or a competitive AR antagonist, Casodex, which competes with androgen for interacting with AR LBD (33) and assessed for the transcriptional activity of AR. 22Rv-1 AI cells showed a decrease in AR activity as assessed by MMTV-Luc assay when treated with PP but were insensitive to Casodex treatment (Fig. 3B) .
However both PP and Casodex inhibited AR activity in 22Rv-1 AD cells (Fig. 3B) . Furthermore, we also utilized MDA-Kb2 cell, a breast cancer cell line stably transfected with MMTV-Luc reporter, for stable transfection with AR ΔLBD using a lentiviral vector. We confirmed the expression of AR ΔLBD in stably transfected MDA-Kb2 cells by Western blotting (Fig. 3C) . Interestingly, overexpression of AR ΔLBD increased level of the endogenous full length AR, which was also observed in AR ΔLBD-transfected LNCaP AD cells (Fig. S1 ) indicating that overexpression of AR ΔLBD somehow increased the stability of the full length AR. To determine the effect of PP and casodex on the transcriptional activity of AR ΔLBD in MDA-Kb2 cells, we treated the control and AR ΔLBD-expressing MDA-Kb2 cells with PP or casodex.
Our results indicated that PP was much more effective than Casodex in inhibiting the MMTV-driven luciferase activity in AR ΔLBD-expressing cell than in the control cell (Fig. 3D) . Together, these results suggest that PP inhibits the activity of both full length AR and AR ΔLBD whereas Casodex was effective only on full length AR and did not inhibit the AR ΔLBD activity in 22Rv-1 AI cells and the transfected AR (Fig. 4) . Quantitative RT-PCR assays showed a relative increase in Hh pathway components, Gli2, Smo and Shh in LNCaP and 22Rv-1 AI cells when compared to their AD cells (Fig. 4A) . We assessed for Gli transcriptional activity using a Gli luciferase assay in which a Gli-responsive promoter luciferase (Gli-Luc) reporter plasmid was co-transfected with a (Fig. 4C) . We also observed a relative increase in the expression of Hh pathway components, Ptch, Gli1 and Gli2 mRNA isolated from mouse prostate after castration as compared to prostate from non-castrated mice (Fig. 4D) . Furthermore, the expression of Hh pathway components was increased in PCa tissues from patients treated with hormone deprivation therapy through an analysis of gene microarray data in Oncomine from a recent study (29) (Fig.   4E) . Together our results demonstrate that Hh pathway components and signaling activity are increased upon androgen deprivation in both in vitro and in vivo conditions suggesting that in addition to truncation mutation of AR, Hh pathway activation may be another mechanism supporting PCa survival and growth under androgen deprivation condition.
Hh signaling is negatively regulated by androgen dependent AR activity. The fact that Hh signaling activity was up-regulated under androgen deprivation condition indicated that Hh signaling activity is suppressed by AR activity. This was demonstrated in a published study by Sirab et al (34) . We took a different approach and showed that overexpression of AR in the untransformed AR negative prostate epithelial cell line BPH-1 (Fig. 5A ) resulted in a decrease in expression of Hh pathway components, Gli1, Gli2 and Smo (Fig. 5B) . On the other hand, AR siRNA mediated silencing of AR in LNCaP AD cells (Fig.   5C ) increased the expression of Hh pathway components, Gli1, Gli2 and Smo (Fig. 5D ) and Gli transcriptional activity as assessed by Gli-responsive promoter luciferase assay (Fig. 5E) . Together, these results suggest that androgen mediated AR activity suppresses Hh signaling. inhibit the growth of CRPC cells. We used Smo inhibitors Cyclopamine and LDE225 in combination with the AR inhibitor PP in a time-course study to assess the inhibition of growth of LNCaP AI cells (Fig. 6A) .
Our results showed that inhibiting with the Smo inhibitor or AR inhibitor alone was only marginally effective or almost had no inhibitory effects, but the combined inhibition was statistically significant in inhibiting the growth of LNCaP AI cells. Another Smo inhibitor GDC0449 was tested alone and in combination with PP on LNCaP AI cells. Similar results were seen with the combination being very effective in inhibiting the AI cell growth compared to individual treatments (Fig. 6B) . To confirm the inhibitory effects on AI cells, we also tested a different AI cell line, 22Rv-1 cells with LDE225 and PP (Fig. 6C) . Similar result with a combination being more effective in inhibiting AI cell proliferation was observed. We also tested LDE225 and PP individually and in combination for their effect on anchorageindependent growth of LNCaP AI cells in soft agar and found that LDE225 and PP individually inhibited the anchorage-independent growth of AI cells moderately, whereas the combination was significantly more effective (Fig. 6D) . However, we did not see the synergistic inhibition of AI cell growth with Casodex + Cyclopamine and Casodex + LDE225 (Fig. S2) , suggesting a significant role of the truncated AR in supporting the growth of the AI cells. We used 5-10 µM of LDE225 and cyclopamine in our MTT assays because this concentration range was found to dose-dependently inhibit Gli transcription activity in the AI cells as shown in the Fig. S3 for LDE225 and Fig. S4 for cyclopamine, yet they showed marginal effect on cell growth (Fig. 6) . Similarly, PP concentration of 50 nM or below was used in our MTT assays as it could inhibit AR transcriptional activity in AI cells (Fig. S5) , but with limited growth inhibitory activity as shown in Fig. 6 . The choice of these drug concentrations led to the demonstration of the synergistic growth inhibition in the AI cells when they were combined.
Combined inhibition of Hh and AR signaling was effective in inhibiting CRPC tumor growth in mice.
To determine if a combinatorial approach can further enhance the efficacy of inhibiting CRPC-mediated prostate tumor progression in vivo, 22Rv-1 AI cells were orthotopically inoculated into athymic male nude mice. Upon detection of tumors with whole mouse bioluminescence imaging, they were castrated and intraperitoneal injection. After 24 days of treatment, the mice were euthanized and prostate isolated for measuring tumor weight from each group. Interestingly, the tumor incidence was reduced from 87.5% in the control group to 50% in the cyclopamine group, 55.6% in the PP group, and 33.3% in the combination group. Furthermore, prostate tumors isolated from mice treated with Cyclopamine+PP showed a statistically significant decrease in tumor weight in comparison to the control group (Fig. 7A) . To accurately track the growth of tumors as a function of cyclopamine and/or PP treatment, we also inoculated the 22Rv-1 AI cells subcutaneously so that we could measure the tumor volume with a caliper at a regular interval. Subcutaneous tumors started to arise in 2 weeks. The mice were ranked according to their tumor burden and divided into four groups with matched tumor burden. All the mice were castrated following regrouping. Four days post castration, vehicle, cyclopamine at 5 mg/kg/day, PP 0.2 at mg/kg/day, or Cyclopamine + PP was given daily through intraperitoneal injection for 11 days and the tumor volume was measured intermittently for each group (Fig. 7B) . Here we present the tumor volume data in 2 ways, 
Discussion
Prostate cancer at its early stage is dependent on androgen for growth and survival. Despite initial response rates of 80-90% of early stage tumor regression after androgen ablation therapy, nearly all men develop androgen-independent prostate cancer after 18-36 months (35) . Majority of prostate cancer related deaths are due to the development of CRPC and metastasis to various organs. The molecular mechanisms that lead to the development of CRPC are not fully understood and currently there is no effective therapy for it.
Although they are refractory to hormone deprivation, CRPC cells are known to express AR and rely on AR activity for survival and proliferation (36). AR activity is maintained under hormone deprivation condition via various mechanisms in CRPC, which include amplification of the AR gene (37;38), missense mutation in AR gene at T877A making it responsive to anti-androgens (39) , and ligand-independent activation of AR by various growth factors such as insulin-like growth factor-1 (IGF-1) (10). In our studies, we observed an increase of AR level in CRPC cells and prostate gland of castrated mice when compared to ADPC cells or non-castrated mice. Interestingly, we observed a decreased transcriptional activity of AR in CRPC cells, presumably due to low androgen in the environment and cytoplasmic localization of inactive AR. Our result that a relative increase in AR level in CRPC cells compared to ADPC cells is consistent with a previous finding that increased androgens represses AR expression (30) . On the other hand, we observed an increased expression of truncated AR proteins (AR ΔLBD) in both LNCaP and 22Rv-1 AI cells.
Previously the AR ΔLBD proteins were shown to be present due to increased proteolytic deletion of the LBD under AI condition in LNCaP cells (40) , whereas they are due to insertion mutation of AR gene and differential RNA splicing of AR transcript in 22Rv-1 cells (41) . Previous studies have demonstrated increased expression levels of AR ΔLBD and its ability to confer resistance to anti-androgens in androgen refractory PCa cells (42) . As expected, AR ΔLBD was found to be insensitive to bicalutamide (Casodex), a competitive AR inhibitor, in our study. However, its transcriptional activity was found to be inhibited by pyrvinium pamoate (PP), a non-competitive AR inhibitor, in CRPC cells suggesting that it is functionally active and may contribute to the development of CRPC as previously suggested (42) .
Another mechanism that contributes to the development of CRPC was the activation of Hh signaling pathway upon hormone deprivation. Previous studies have shown that Hh signaling pathway is activated during prostate tumorigenesis and progression (43;44) . More recent studies showed that androgen deprivation upregulated the expression of Hedgehog signaling components and consequently Hh signaling activity in prostate cancer cell lines and circulating prostate tumor cells (23;24). Our study not only confirmed the published findings in the prostate cancer cells, but also demonstrated upregulation of Hh pathway components in vivo in the human CWR22 prostate cancer xenograft tumors upon surgical androgen deprivation. Our study also confirmed a previous report demonstrating increased Hh components in the prostate gland of castrated mice (45) . Consistent with these findings, genetic approaches with ectopic expression or knockdown of AR with siRNA also showed that AR level is inversely related with Hh pathway components and Gli transcriptional activity suggesting a direct suppression of Hh signaling activity by AR. As a result, androgen deprivation led to an enhanced autocrine Hh signaling activity, which can be dose-dependently inhibited by the treatment with Smo inhibitor, LDE225 in our study ( Supplementary Fig. 3 ), or genetic knockdown of Smo (46) . These findings suggest that the increased Hh signaling and AR ΔLBD expression might contribute to the development and maintenance of CRPC. Thus, to inhibit the development and proliferation of CRPC cells, we used Hh and AR inhibitors independently and in combination both under in vitro and in vivo conditions. We demonstrated that the non-competitive AR inhibitor PP was effective in inhibiting the AR activity in 22Rv-1 AI cells whereas the competitive AR inhibitor casodex was ineffective even though Casodex showed inhibition of AR activity similar to PP in androgen dependent 22Rv-1 cells. Hence a noncompetitive AR inhibitor is effective in inhibiting AR activity under AI condition. Significantly, while various Smo inhibitors showed little or no effect on the growth of CRPC cells in micromolar concentrations, they produced synergistic inhibition of CRPC cell growth in combination with suboptimal concentrations of PP. Furthermore, the combination of PP with cyclopamine was found more effective than either agent alone in inhibiting the growth of CRPC tumors in vivo.
In summary, our study demonstrated activation of Hh signaling in both in vitro and in vivo models 
